Search

Your search keyword '"Tovoli, F"' showing total 219 results
Start Over Author "Tovoli, F" Publication Type Academic Journals
219 results on '"Tovoli, F"'

2. Presence of Hepatocellular Carcinoma Does Not Affect Course and Response to Anticoagulation of Bland Portal Vein Thrombosis in Cirrhotic Patients

Author

Benevento F, Pecorelli A, Stefanescu H, Sparchez Z, Vukotic R, Pettinari I, Grigoras CA, Tovoli F, Ravaioli F, Stefanini B, Andreone P, and Piscaglia F

Subjects
lc: liver cirrhosis, hcc: hepatocellular carcinoma, pvt: portal vein thrombosis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Francesca Benevento,1 Anna Pecorelli,2 Horia Stefanescu,3 Zeno Sparchez,3 Ranka Vukotic,1,4 Irene Pettinari,2 Crina-Anca Grigoras,3 Francesco Tovoli,1,5 Federico Ravaioli,1 Bernardo Stefanini,1 Pietro Andreone,6 Fabio Piscaglia1,5 1Department of Medicine and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy; 2Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 3Gastroenterology Department, Liver Unit & Ultrasound Laboratory, Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania; 4Medicina Interna 4, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; 5Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 6Divisione di Medicina Interna a Indirizzo Metabolico-Nutrizionale, Azienda Ospedaliero-Universitaria di Modena, Modena, ItalyCorrespondence: Fabio Piscaglia, Email Fabio.piscaglia@unibo.itBackground: Malignancies are generally considered a risk factor for deep vein thrombosis and may hamper the recanalisation of thrombosed veins.Aim: We investigate whether the natural course and response to anticoagulant treatment of bland portal vein thrombosis (PVT) in patients with cirrhosis complicated by hepatocellular carcinoma (HCC) differ from those without HCC.Methods: Retrospective study in two hepatology referral centres, in Italy and Romania where patients with a diagnosis of PVT on cirrhosis and follow-up of at least 3 months with repeated imaging were included.Results: A total of 162 patients with PVT and matching inclusion and exclusion criteria were identified: 30 with HCC were compared to 132 without HCC. Etiologies, Child-Pugh Score (7 vs 7) and MELD scores (11 vs 12, p=0.3679) did not differ. Anticoagulation was administered to 43% HCC vs 42% nonHCC. The extension of PVT in the main portal trunk was similar: partial/total involvement was 73.3/6.7% in HCC vs 67.4/6.1% in nonHCC, p=0.760. The remainder had intrahepatic PVT. The recanalization rate was 61.5% and 60.7% in HCC/nonHCC in anticoagulated patients (p=1). Overall PVT recanalisation, including treated and untreated patients, was observed in 30% of HCC vs 37.9% of nonHCC, p=0.530. Major bleeding incidence was almost identical (3.3% vs 3.8%, p=1). Progression of PVT after stopping anticoagulation did not differ (10% vs 15.9%, respectively, HCC/nHCC, p=0.109).Conclusion: The course of bland non-malignant PVT in cirrhosis is not affected by the presence of active HCC. Treatment with anticoagulation in patients with active HCC is safe and as effective as in nonHCC patients, this can potentially allow us to use otherwise contraindicated therapies (ie TACE) if a complete recanalization is achieved with anticoagulation.Keywords: LC, liver cirrhosis, HCC, hepatocellular carcinoma, PVT, portal vein thrombosis

Published
2023

4. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon

Author

Petta, S., Cabibbo, G., Barbara, M., Attardo, S., Bucci, L., Farinati, F., Giannini, E. G., Tovoli, F., Ciccarese, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Sacco, R., Virdone, R., Marra, F., Felder, M., Morisco, F., Benvegnù, L., Gasbarrini, A., Svegliati‐Baroni, G., Foschi, F. G., Olivani, A., Masotto, A., Nardone, G., Colecchia, A., Persico, M., Boccaccio, V., Craxì, A., Bruno, S., Trevisani, F., Cammà, C., Biselli, Maurizio, Caraceni, Paolo, Cucchetti, Alessandro, Domenicali, Marco, Piscaglia, Fabio, Gramenzi, Annagiulia, Granito, Alessandro, Magalotti, Donatella, Serra, Carla, Negrini, Giulia, Napoli, L., Napoli, Lucia, Salvatore, Veronica, Benevento, Francesca, Gazzola, Alessia, Murer, Francesca, Pozzan, Caterina, Vanin, Veronica, Moscatelli, Alessandro, Pellegatta, Gaia, Picciotto, Antonino, Savarino, Vincenzo, Poggio, Paolo Del, Olmi, Stefano, de Matthaeis, Nicoletta, Balsamo, Claudia, Vavassori, Elena, Roselli, Paola, DellʼIsola, Serena, Ialungo, Anna Maria, Rastrelli, Elena, Rini, Francesca, Costantino, Andrea, Affronti, Andrea, Affronti, Marco, Mascari, Marta, Mega, Andrea, Pompili, Maurizio, Rinninella, Emanuele, Mismas, Valeria, DallʼAglio, Anna Chiara, Feletti, Valentina, Lanzi, Arianna, Cappa, Federica Mirici, Neri, Elga, Stefanini, Giuseppe Francesco, Tamberi, Stefano, Biasini, Elisabetta, Missale, Gabriele, Guarino, Maria, Ortolani, Alessio, Chiaramonte, Maria, Marchetti, Fabiana, Valerio, Matteo, Aburas, Sami, Inghilesi, Andrea L., Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Coccoli, Piero, and Zamparelli, Marco Sanduzzi

Published
2017
Full Text
View/download PDF

7. The synergic effect of metformin with atezolizumab/ bevacizumab in masld hcc patients: a retrospective study from arte multicentric Italian dataset

Author

Dalbeni, A., Vicardi, M., Natola, L.A., Auriemma, A., Stefanini, B., Vivaldi, C., Federico, P., Palloni, A., Soldà, C., Lani, L., Garajova, I., Tamberi, S., De Lorenzo, S., Piscaglia, F., Milella, M., Masi, G., Lonardi, S., Brandi, G., Daniele, B., Trevisani, F., Svegliati-Baroni, G., Marra, F., Tovoli, F., and Sacerdoti, D.

Published
2024
Full Text
View/download PDF

9. Efficacy and safety of atezolizumab/bevacizumab for hepatocellular carcinoma in a real-life prospective cohort: data from a multicenter collaborative study

Author

Tovoli, F., Vivaldi, C., Federico, P., Stefanini, B., Palloni, A., Dalbeni, A., Soldà, C., Lani, L., Garajova, I., Tamberi, S., De Lorenzo, S., Granito, A., Pallotta, D.P., Masi, G., Lonardi, S., Brandi, G., Daniele, B., Sacerdoti, D., Svegliati-Baroni, G., Campani, C., Pellegrini, E., and Piscaglia, F.

Published
2024
Full Text
View/download PDF

20. Clinical impact of relative dose intensity of cabozantinib during the first 8 weeks and of subsequent dose reductions in patients with unresectable hepatocellular carcinoma

Author

Tovoli, F., Dadduzio, V., De Lorenzo, S., Rimassa, L., Masi, G., Iavarone, M., Marra, F., Garajova, I., Brizzi, M.P., Daniele, B., Trevisani, F., Messina, C., Clemente, F. Di, Pini, S., Cabibbo, G., Granito, A., Rizzato, M.D., Zagonel, V., Brandi, G., Pressiani, T., Federico, P., Vivaldi, C., Bergna, I., Campani, C., and Piscaglia, F.

Published
2023
Full Text
View/download PDF

22. P-57 Atezolizumab in combination with bevacizumab in patients with unresectable HCC previously untreated with systemic therapy: Interim analysis results from phase IIIb Italian AMETHISTA trial

Author

Martinelli, E., Masi, G., Piscaglia, F., Cabibbo, G., Di Maio, M., Gasbarrini, A., Iavarone, M., Pellegrini, E., Mazzaferro, V., Ballestrero, A., Garufi, C., Bergamo, F., Celsa, C., Marino, D., Tovoli, F., Ponziani, F., Pressiani, T., Astolfi, C., Ciardiello, F., Daniele, B., and Rimassa, L.

Published
2023
Full Text
View/download PDF

24. Occupational exposure and risk of complications in MASLD patients:updates from a case:control study.

Author

Stefanini, B., Mandrioli, D., Vornoli, A., Salomone, A., Sgargi, D., Manservisi, F., Piscaglia, F., and Tovoli, F.

Abstract

Pollutants are increasingly being evaluated as possible contributors to the progression of liver damage in metabolic dysfunction-associated steatotic liver disease (MASLD). Recently, we published a case-control study showing that patients with MASLD-related advanced chronic liver disease (ACLD) and/or hepatocellular carcinoma (HCC) were more likely to report workplace toxicant exposure compared to those with uncomplicated MASLD. Consequently, an extension of the accrual and a transition to a multicenter study were decided. To provide updated evidence following the first extension of the cohort from our original study, which aimed to assess the prevalence of self-reported occupational exposure to toxicants in patients with MASLD. After the extension, this hospital-based prospective pilot study include 224 patients with MASLD. Data on workplace toxicant exposure were collected systematically using a structured questionnaire. Subsequently, patients with ACLD and/or HCC (n = 65) were compared to controls (n = 159). Logistic regression analysis and propensity score models were used to investigate the associations between self-reported occupational exposure and ACLD and/or HCC. The updated data confirmed that patients with ACLD/HCC are more likely to report exposure to metals, halogenated refrigerants, paint/resins, and fuel emissions than the controls. Durations of 21-30 years and >30 years of occupational exposure to toxicants were also more frequently associated with ACLD/HCC, with odds ratios (ORs) of 2.42 (95% confidence interval [CI]: 1.11-4.94, p = 0.020) and 4.21 (95% CI: 2.36-7.53, p < 0.001), respectively. These associations were confirmed after corrections for demographics and other confounders. The extension of our cohort confirms that patients with MASLD complications are more likely to report workplace toxicant exposure than controls. A transition to a multicenter effort is underway. If confirmed, our results may help in developing prevention policies to reduce the risk of life-threatening diseases among exposed populations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. T.08.3 CHARACTERISTICS AND SURVIVAL OF PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AND HEPATOCELLULAR CARCINOMA

Author

Giannini, E.G., Pieri, G., Labanca, S., Plaz Torres, M.C., Gasbarrini, A., Biasini, E., Campani, C., Cazzagon, N., Foschi, F.G., Mega, A., Masotto, A., Raimondo, G., Rapaccini, G.L., Sacco, R., Caturelli, E., Guarino, M., Tovoli, F., Vidili, G., Brunetto, M.R., Nardone, G., Svegliati-Baroni, G., Magalotti, D., Azzaroli, F., Cabibbo, G., Di Marco, M., Sangiovanni, A., and Trevisani, F.

Published
2022
Full Text
View/download PDF

33. Real-life clinical data of cabozantinib for unresectable hepatocellular carcinoma: efficacy, safety and prognostic factors

Author

Tovoli, F., Dadduzio, V., De Lorenzo, S., Rimassa, L., Masi, G., Iavarone, M., Marra, F., Garajova, I., Brizzi, M.P., Daniele, B., Trevisani, F., Messina, C., Clemente, F. Di, Pini, S., Cabibbo, G., Granito, A., Rizzato, M.D., Zagonel, V., Brandi, G., Pressiani, T., Federico, P., Vivaldi, C., Bergna, I., Campani, C., and Piscaglia, F.

Published
2021
Full Text
View/download PDF

45. Increased risk of nonalcoholic fatty liver disease in patients with coeliac disease on a gluten‐free diet: beyond traditional metabolic factors.

Author

Tovoli, F., Negrini, G., Farì, R., Guidetti, E., Faggiano, C., Napoli, L., Bolondi, L., and Granito, A.

Subjects
*CELIAC disease, *CELIAC disease treatment, *FATTY liver, *FATTY liver prevention, *METABOLIC syndrome, *PATIENTS
Abstract

Summary: Background: A gluten‐free diet (GFD) is known to be associated with altered macronutrient intake and metabolic syndrome. Nonalcoholic fatty liver disease (NAFLD) is the hepatic hallmark of metabolic syndrome. The risk of NAFLD in patients with coeliac disease (CD) adhering to a GFD remains to be fully investigated; in particular, data from real‐life clinical settings are lacking. Aim: To assess the prevalence and relative risk of NAFLD in CD patients treated with a GFD. Methods: Case–control study, with prospective enrolment of CD outpatients following a GFD and controls. Patients were matched for demographic characteristics (age and gender) and metabolic risk factors (overweight, diabetes mellitus, total cholesterol, and triglycerides) using a 1:1 ratio. NAFLD was diagnosed according to the European Association for the Study of the Liver criteria. Results: 202 CD patients and 202 controls were compared. The raw prevalence of NAFLD was 34.7% and 21.8% in the CD and control group, respectively (P = 0.006). Binary logistic regression confirmed an increased risk of NAFLD in the CD group (adjusted odds ratio = 2.90, 95% confidence interval: 1.64‐5.15, P < 0.001). Additionally, the relative risk for NAFLD was notably higher in non‐overweight CD patients (adjusted odds ratio = 5.71, 95% confidence interval: 2.30‐14.19, P < 0.001). Conclusions: More than one‐third of CD patients adhering to a GFD had concurrent NAFLD, accounting for a three‐fold increased risk compared to the general population. Dietary advice provided using a patient‐tailored approach should assist CD patients with NAFLD in achieving an appropriate nutritional intake whilst reducing the risk of long‐term liver‐related events. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results